Drugs Made in America Acquisition Corp. Shareholders Approve Extension to Complete Business Combination

Key Highlights

• Extraordinary General Meeting Held: On April 27, 2026, Drugs Made in America Acquisition Corp. (“the Company”) hosted an extraordinary general meeting for shareholders.
• Extension of Business Combination Deadline: Shareholders approved a special resolution to amend the Company’s charter, allowing up to 12 one-month extensions of the deadline to consummate a business combination, moving the final potential date from April 29, 2026 to April 29, 2027.
• Financial Commitment for Extensions: For each monthly extension, the Company’s sponsor is required to deposit the lesser of \$300,000 or \$0.04 per non-redeemed public share into the trust account.
• Shareholder Redemptions: In connection with the extension vote, holders of 9,440,230 ordinary shares (out of 33,517,143 outstanding) exercised their right to redeem, resulting in \$99,336,016.67 (approximately \$10.52 per share) being withdrawn from the trust account and returned to redeeming shareholders.
• Significant Impact on Public Float: This redemption reduces the number of public shares, concentrating ownership and potentially impacting future trading liquidity and share price volatility.
• Trading Details: The Company’s units (DMAAU), ordinary shares (DMAA), and rights (DMAAR) continue to trade on the NASDAQ Stock Market.

Details of the Approved Extension

The approved amendment to the Second Amended and Restated Memorandum and Articles of Association enables the Company to extend the time frame to complete a business combination in monthly increments, up to 12 times, for a total of one additional year. Each extension is conditional upon the sponsor’s deposit of the lesser of \$300,000 or \$0.04 per non-redeemed public share for each extension month into the trust account. If the Company fails to consummate a business combination by April 29, 2027, and the required deposits are made, it must redeem 100% of the remaining public shares.

Shareholder Vote Results

At the record date of April 7, 2026, there were 33,517,143 ordinary shares outstanding. At the meeting, 23,798,927 shares were represented in person or by proxy (approximately 70.58% of outstanding shares), establishing a quorum. The extension proposal was approved by special resolution.

Shareholder Redemptions and Trust Account Impact

The redemption election by holders of 9,440,230 shares equates to a significant capital outflow from the trust account, totaling \$99,336,016.67. This not only reduces the capital base available for a future business combination but also increases the redemption price per share for any future redemptions, as there are now fewer outstanding shares.

The substantial redemption may signal uncertainty among shareholders regarding the likelihood or attractiveness of a future business combination. It also reduces the public float, which could increase volatility in the trading price of the Company’s shares and units.

Implications for Shareholders and Potential Price Sensitivity

• Reduced Public Float: The significant redemption of public shares could lead to increased volatility and decreased liquidity in DMAA, DMAAU, and DMAAR securities.
• Increased Sponsor Influence: With fewer public shares outstanding, the sponsor may have a relatively greater influence over the outcome of any future shareholder votes.
• Ongoing Uncertainty: The extension buys more time to pursue a business combination, but the lack of a definitive merger target may create ongoing uncertainty, potentially weighing on the share price in the interim.
• Potential for Further Redemptions: Should the Company announce a business combination deemed unattractive by remaining shareholders, further redemptions could occur, further affecting the Company’s capital and trading profile.
• Trust Account Depletion: Each monthly extension reduces the trust account by up to \$300,000, decreasing the funds available for a potential business combination or for future redemptions.

Conclusion

The extension of the business combination deadline, significant redemptions, and resulting reduction in the trust account are all material developments for investors in Drugs Made in America Acquisition Corp. These actions may impact the trading price and liquidity of the Company’s securities and are likely to be closely watched by market participants.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell any securities. Investors should conduct their own due diligence and consult with their financial advisor before making any investment decisions. The information contained herein is based on publicly available filings and may be subject to change or clarification in future disclosures.

View Drugs Made In America Acquisition Corp. Historical chart here